Doses reported in published research
Sources checked 2026-10-07
For each compound, these pages list the amounts, routes and schedules that published studies and trial registrations report, with the citation and the source wording for every figure. Animal and human data are kept separate, and pages say plainly where no human data exist.
Compounds
| Compound | Cited studies | Human | Animal | Cell culture | Registered trials |
|---|---|---|---|---|---|
| ARA-290 (cibinetide) | 5 | 4 | 1 | 0 | 3 |
| BPC-157 | 5 | 2 | 3 | 0 | 3 |
| Cartalax | 1 | 0 | 0 | 1 | 0 |
| CJC-1295 (with DAC) | 3 | 2 | 1 | 0 | 0 |
| DSIP | 5 | 3 | 2 | 0 | 0 |
| Epitalon | 3 | 0 | 3 | 0 | 0 |
| FOXO4-DRI | 3 | 0 | 2 | 1 | 0 |
| GHK-Cu | 3 | 0 | 3 | 0 | 0 |
| GHRP-6 | 6 | 4 | 2 | 0 | 0 |
| IGF-1 LR3 | 3 | 0 | 3 | 0 | 0 |
| Ipamorelin | 4 | 2 | 2 | 0 | 1 |
| Klotho (α-Klotho) | 8 | 0 | 8 | 0 | 0 |
| KPV | 1 | 0 | 1 | 0 | 0 |
| LL-37 | 2 | 2 | 0 | 0 | 1 |
| MOTS-c | 3 | 0 | 3 | 0 | 1 |
| PE-22-28 | 2 | 0 | 2 | 0 | 0 |
| Selank | 4 | 0 | 4 | 0 | 0 |
| Semax | 3 | 1 | 2 | 0 | 0 |
| SS-31 (elamipretide) | 7 | 4 | 3 | 0 | 0 |
| TB-500 (thymosin beta-4) | 7 | 4 | 3 | 0 | 0 |
| Thymagen (Thymogen) | 2 | 0 | 2 | 0 | 0 |
| Thymalin | 1 | 0 | 1 | 0 | 0 |
| Thymosin alpha-1 | 5 | 5 | 0 | 0 | 0 |
GLP-class compounds
Approved versions of semaglutide and tirzepatide exist only as prescription drugs; the other compounds here are investigational. These pages summarize FDA labels and published trials.
| Compound | Cited studies | Human | Animal | Cell culture | Registered trials |
|---|---|---|---|---|---|
| Cagrilintide | 2 | 2 | 0 | 0 | 0 |
| Retatrutide | 4 | 4 | 0 | 0 | 0 |
| Semaglutide | 4 | 4 | 0 | 0 | 0 |
| Survodutide | 3 | 3 | 0 | 0 | 0 |
| Tirzepatide | 4 | 4 | 0 | 0 | 0 |
Not enough published data
No page for: CJC-1295 (no DAC). We found no study that states an amount for it under its own name.
Compounds kept off the shop and profile pages for risk reasons are not covered here either.